Allergan has entered into a definitive agreement to acquire Tobira Pharmaceuticals, a clinical-stage biopharma company developing therapies for non-alcoholic steatohepatitis (NASH) and other liver disease, for a total potential consideration of $1.7 billion in cash and certain development, regulatory and commercial milestones. The boards of directors of both companies have approved the transaction and Allergan anticipates closing by the end of 2016.   NASH is a severe type of non-alcoholic fat...